

# Giancarlo Comi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5740539/giancarlo-comi-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

361  
papers

28,388  
citations

76  
h-index

162  
g-index

388  
ext. papers

34,313  
ext. citations

7.9  
avg, IF

6.67  
L-index

#	Paper	IF	Citations
361	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 162-173	24.1	2419
360	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 402-15	59.2	1686
359	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , <b>2014</b> , 83, 278-86	6.5	1632
358	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , <b>2001</b> , 357, 1576-82	40	884
357	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 209-220	59.2	880
356	Oral fingolimod (FTY720) for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 1124-40	59.2	877
355	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 221-234	59.2	858
354	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> , <b>1997</b> , 120 ( Pt 11), 2059-69	11.2	832
353	Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1293-303	59.2	662
352	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2001</b> , 49, 290-297	9.4	624
351	A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 416-26	59.2	591
350	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISE study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1503-11	40	475
349	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , <b>2018</b> , 391, 1263-1273	40	422
348	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 247-56	24.1	363
347	250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology, The</i> , <b>2009</b> , 8, 889-97	24.1	338
346	A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. <i>Neurology</i> , <b>1995</b> , 45, 478-82	6.5	332
345	Placebo-controlled trial of oral laquinimod for multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1000-9	59.2	290

344	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 96-120	5	286
343	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , <b>1998</b> , 43, 809-14	9.4	283
342	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 1122-31	6	276
341	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 705-16	5	237
340	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , <b>2008</b> , 371, 2085-92	40	236
339	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. <i>Neurology</i> , <b>1998</b> , 50, 1601-8	6.5	230
338	Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. <i>Neurology</i> , <b>1999</b> , 52, 588-94	6.5	226
337	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2004</b> , 364, 1489-96	40	215
336	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1082-91	5.5	209
335	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 977-86	24.1	208
334	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. <i>Annals of Neurology</i> , <b>2012</b> , 72, 610-24	9.4	201
333	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 574-84	24.1	194
332	Typical and atypical pathology in primary progressive aphasia variants. <i>Annals of Neurology</i> , <b>2017</b> , 81, 430-443	9.4	192
331	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 780-789	9.4	189
330	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , <b>2017</b> , 389, 1347-1356	40	185
329	Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , <b>2002</b> , 195, 103-9 <sup>2</sup>	3.2	185
328	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
327	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 520-9	24.1	178

326	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. <i>Annals of Neurology</i> , <b>2001</b> , 49, 290-7	9.4	170
325	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1452-68	5.5	161
324	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 257-67	24.1	156
323	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology</i> , <b>2012</b> , 11, 33-41	24.1	153
322	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1995</b> , 132, 222-7	3.2	150
321	Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. <i>Journal of Cell Science</i> , <b>2006</b> , 119, 3981-93	5.3	149
320	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. <i>Journal of Neurology</i> , <b>1997</b> , 244, 266-70	5.5	148
319	Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. <i>Brain</i> , <b>1996</b> , 119 ( Pt 4), 1349-55	11.2	147
318	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1594-1604	5	140
317	Physiopathology and treatment of fatigue in multiple sclerosis. <i>Journal of Neurology</i> , <b>2001</b> , 248, 174-9	5.5	137
316	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. <i>Neurology</i> , <b>2010</b> , 75, 2121-8	6.5	135
315	Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 197-207	5	134
314	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 546-557	59.2	132
313	Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. <i>Neurology</i> , <b>2000</b> , 55, 940-6	6.5	130
312	A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1370-7	5.5	123
311	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2016</b> , 15, 373-81	24.1	118
310	Functional basis of memory impairment in multiple sclerosis: a [18F]FDG PET study. <i>NeuroImage</i> , <b>1996</b> , 4, 87-96	7.9	117
309	Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 267-74	5.8	115

308	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , <b>2000</b> , 55, 1714-8	6.5	114
307	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. <i>Neurology</i> , <b>1996</b> , 46, 379-84	6.5	110
306	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 468-75	5.5	109
305	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2009</b> , 66, 513-20	9.4	109
304	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , <b>1996</b> , 243, 502-5	5.5	108
303	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , <b>2004</b> , 62, 1432-4	6.5	106
302	Heterogeneity of autoantibodies in stiff-man syndrome. <i>Annals of Neurology</i> , <b>1993</b> , 34, 57-64	9.4	106
301	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 267-76	5.5	100
300	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 1021-1033	24.1	98
299	Brain structural and functional connectivity in Parkinson's disease with freezing of gait. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 5064-78	5.9	97
298	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , <b>2000</b> , 247, 506-9	5.5	97
297	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 1009-1020	24.1	96
296	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 215-237	6	96
295	Impaired functional integration in multiple sclerosis: a graph theory study. <i>Brain Structure and Function</i> , <b>2016</b> , 221, 115-31	4	90
294	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orally) study. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 578-93	5	88
293	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Human Brain Mapping</i> , <b>2004</b> , 21, 108-17	5.9	85
292	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 851-8	5.5	84
291	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1386-1396	5	83

290	Corpus callosum damage and cognitive dysfunction in benign MS. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 2656-66	6.6	82
289	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , <b>2014</b> , 83, 1432-8	6.5	78
288	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2000</b> , 69, 192-8	5.5	77
287	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1993</b> , 115 Suppl, S66-73	3.2	76
286	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , <b>2016</b> , 87, 134-40	6.5	74
285	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 147-55	5	72
284	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2023-32	5.5	72
283	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1074-83	5	72
282	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 459-471	5	71
281	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e19992	7.6	70
280	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 133-41	4.1	66
279	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , <b>2009</b> , 73, 1842-8	6.5	65
278	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 29, 157-167	4	65
277	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 511-9	5	64
276	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 1710-22	5.9	64
275	Structural brain correlates of cognitive and behavioral impairment in MND. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 1614-26	5.9	64
274	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 3275-86	11.2	63
273	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 944-51	5.5	63

272	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 1344-50	5.5	62
271	Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training. <i>Journal of Neurology</i> , <b>2017</b> , 264, 88-101	5.5	60
270	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 245, 111-6	3.2	60
269	Disrupted brain connectome in semantic variant of primary progressive aphasia. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2646-2655	5.6	59
268	Mitoxantrone: benefits and risks in multiple sclerosis patients. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S167-70	3.5	59
267	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 29, 168-174	4	54
266	Brain network connectivity differs in early-onset neurodegenerative dementia. <i>Neurology</i> , <b>2017</b> , 89, 1766-1772	5.3	53
265	Event-related desynchronization to contingent negative variation and self-paced movement paradigms in Parkinson's disease. <i>Movement Disorders</i> , <b>1998</b> , 13, 653-60	7	53
264	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1360-6	5	52
263	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , <b>2016</b> , 139, 2740-2750	11.2	51
262	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1870-e1885	6.5	50
261	Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. <i>American Journal of Neuroradiology</i> , <b>1998</b> , 19, 223-9	4.4	47
260	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1315-26	5	46
259	Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. <i>Neurological Sciences</i> , <b>2011</b> , 31 Suppl 3, 299-302	3.5	46
258	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2000</b> , 247, 960-5	5.5	46
257	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 147-55	4	43
256	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , <b>2019</b> , 40, 155-165	3.5	42
255	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , <b>2019</b> , 85, 371-384	9.4	42

254	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 433	4.1	41
253	Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 5051-63	5.9	41
252	Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. <i>Annals of Neurology</i> , <b>1998</b> , 43, 340-9	9.4	41
251	Multimodal structural MRI in the diagnosis of motor neuron diseases. <i>NeuroImage: Clinical</i> , <b>2017</b> , 16, 240-247	5.3	40
250	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 171, 135-44	3.2	40
249	Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1084-94	5	39
248	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , <b>2017</b> , 140, 2814-2819	11.2	38
247	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756285617753365	6.6	38
246	Disease-modifying treatments for progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1428-36	5	38
245	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1194-1203	5	38
244	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , <b>2021</b> , 89, 13-23	9.4	38
243	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 189-97	5	37
242	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1144-53	5	37
241	White Matter Degeneration in Atypical Alzheimer Disease. <i>Radiology</i> , <b>2015</b> , 277, 162-72	20.5	37
240	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. <i>Journal of Neurology</i> , <b>1989</b> , 236, 4-8	5.5	37
239	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 627-636	5	37
238	Changes in functional and structural brain connectome along the Alzheimer's disease continuum. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 230-239	15.1	37
237	Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2520-7	5.5	36



236	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1506-1508	5	36
235	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 155-164	24.1	36
234	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 1738-1744	5.3	36
233	Structural and functional brain signatures of C9orf72 in motor neuron disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 57, 206-219	5.6	35
232	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , <b>2017</b> , 264, 2436-2449	5.5	35
231	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1727-35	5.5	35
230	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 68, 409-11	9.4	35
229	Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. <i>Neuropharmacology</i> , <b>2013</b> , 67, 1-7	5.5	34
228	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1157-1162	5	34
227	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1864-1874	5	33
226	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1136-46	5.5	33
225	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , <b>2017</b> , 77, 1755-1768	12.1	33
224	Multiple sclerosis: pseudotumoral forms. <i>Neurological Sciences</i> , <b>2004</b> , 25 Suppl 4, S374-9	3.5	33
223	Noninvasive Neuromodulation in Poststroke Gait Disorders: Rationale, Feasibility, and State of the Art. <i>Neurorehabilitation and Neural Repair</i> , <b>2016</b> , 30, 71-82	4.7	32
222	Deep repetitive transcranial magnetic stimulation with H-coil on lower limb motor function in chronic stroke: a pilot study. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>2014</b> , 95, 1141-7	2.8	32
221	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1647-1650	3.5	31
220	Peripheral nerve morphogenesis induced by scaffold micropatterning. <i>Biomaterials</i> , <b>2014</b> , 35, 4035-4045	5.6	31
219	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2472-80	5.5	31

218	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 819-827	5	31
217	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1183-1195	5	30
216	Resting state functional connectivity alterations in primary lateral sclerosis. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 916-25	5.6	30
215	Induction vs. escalating therapy in multiple sclerosis: practical implications. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S253-5	3.5	30
214	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , <b>2019</b> , 92, e733-e741	6.5	30
213	Evaluation of an optimized [ F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 687-e26	6	29
212	Structural brain abnormalities in patients with vestibular migraine. <i>Journal of Neurology</i> , <b>2017</b> , 264, 295-303	3.9	28
211	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. <i>Radiology</i> , <b>2018</b> , 288, 234-244	20.5	28
210	Brain MR Imaging in Patients with Lower Motor Neuron-Predominant Disease. <i>Radiology</i> , <b>2016</b> , 280, 545-555	5.6	28
209	Extramotor damage is associated with cognition in primary lateral sclerosis patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e82017	3.7	28
208	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2020</b> , 19, 988-997	24.1	28
207	Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry. <i>Stroke</i> , <b>2016</b> , 47, 1702-9	6.7	27
206	Excitatory deep repetitive transcranial magnetic stimulation with H-coil as add-on treatment of motor symptoms in Parkinson's disease: an open label, pilot study. <i>Brain Stimulation</i> , <b>2014</b> , 7, 297-300	5.1	27
205	White matter microstructure abnormalities in pediatric migraine patients. <i>Cephalalgia</i> , <b>2015</b> , 35, 1278-86	6.1	27
204	Effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , <b>2001</b> , 49, 415-416	9.4	27
203	Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 40136	4.9	27
202	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2016</b> , 29, 243-53	7.1	27
201	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 81, 729-739	9.4	26

200	Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 6005-6018	5.9	26
199	Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 59	19	26
198	Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 372-381	5	26
197	Cerebrospinal Fluid Amyloid- $\beta$ 2, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 183-200	4.3	25
196	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. <i>NeuroImage: Clinical</i> , <b>2018</b> , 17, 145-152	5.3	25
195	Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. <i>European Neurology</i> , <b>1993</b> , 33, 232-7	2.1	25
194	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1255-1262	5	24
193	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 257-266	1.2	24
192	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 347-359	5	24
191	Subcutaneous interferon $\beta$ 1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 285-294	5.5	23
190	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 39-44	6	23
189	MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis. <i>Radiology</i> , <b>2016</b> , 279, 553-61	20.5	23
188	Pediatric versus adult MS: similar or different?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2017</b> , 2,	0	23
187	Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>1998</b> , 4, 260-5	5	23
186	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , <b>2019</b> , 85, 606-610	9.4	23
185	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1600-1613	5	22
184	Multispectral MRI with Dual Fluorinated Probes to Track Mononuclear Cell Activity in Mice. <i>Radiology</i> , <b>2019</b> , 291, 351-357	20.5	22
183	Autologous bone marrow transplantation for the treatment of multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , <b>2014</b> , 14, 478	6.6	22

182	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , <b>2017</b> , 38, 53-59	3.5	22
181	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 286, 109-13	3.2	22
180	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , <b>2020</b> , 143, 2637-2652	11.2	22
179	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 956-9	5	21
178	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 2293-304	5.9	21
177	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2012</b> , 1, 49-54	4	21
176	Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 123-36	4	21
175	Treatment of multiple sclerosis: role of natalizumab. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S155-8	3.5	21
174	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035318	5	21
173	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 628-40	5	20
172	Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. <i>Radiology</i> , <b>2015</b> , 276, 219-27	20.5	20
171	Relapses in patients treated with fingolimod after previous exposure to natalizumab. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 786-90	5	20
170	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1781-8	5.5	20
169	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 383, 166-168	3.2	20
168	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 3013-3024	11.2	20
167	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 399-407	5	20
166	Expanding the spectrum of genes responsible for hereditary motor neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1171-1179	5.5	19
165	A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2336-45	5.5	19

164	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318760642	2	19
163	Axonal neuropathy associated with interferon-alpha treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. <i>Acta Neuropathologica</i> , <b>1997</b> , 94, 504-8	14.3	19
162	Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 247-255	4.1	19
161	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis <b>2001</b> , 49, 290		19
160	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. <i>Neurological Sciences</i> , <b>2016</b> , 37, 1399-402	3.5	18
159	Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, S261-4	3.5	18
158	The first year after diagnosis: psychological impact on people with multiple sclerosis. <i>Psychology, Health and Medicine</i> , <b>2017</b> , 22, 1063-1071	2.1	17
157	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2017</b> , 3, 2055217317732802	2	17
156	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 33-40	4	17
155	Functional and structural plasticity following action observation training in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1472-1487	5	17
154	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. <i>Journal of the Neurological Sciences</i> , <b>2000</b> , 172 Suppl 1, S63-6	3.2	17
153	COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	17
152	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 1495-1508	4.3	17
151	Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 32, 123-132	4	16
150	Efficacy of subcutaneous interferon $\beta$ 1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 647-53	5.5	16
149	Clinically isolated syndrome: the rationale for early treatment. <i>Nature Clinical Practice Neurology</i> , <b>2008</b> , 4, 234-5		16
148	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 204-216	5	16
147	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 208-217	6.4	16

146	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 331-346	5	16
145	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , <b>2017</b> , 136, 454-461	3.8	15
144	Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2440-2	5.5	15
143	Following the Spreading of Brain Structural Changes in Alzheimer's Disease: A Longitudinal, Multimodal MRI Study. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 995-1007	4.3	15
142	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , <b>2011</b> , 32, 351-8	3.5	15
141	Neurophysiological correlates of cognitive disturbances in multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, S249-53	3.5	15
140	Neurophysiologic studies and cognitive function in congenital hypothyroid children. <i>Pediatric Research</i> , <b>1995</b> , 37, 736-40	3.2	15
139	Structural connectivity in multiple sclerosis and modeling of disconnection. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 220-232	5	15
138	Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 201	4.1	15
137	Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2272-2280	5.5	15
136	The role of clinical and neuroimaging features in the diagnosis of CADASIL. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2934-2943	5.5	15
135	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 262-270	7.1	14
134	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 167-174	5	14
133	Cognitive impairment in progressive supranuclear palsy-Richardson's syndrome is related to white matter damage. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 31, 65-71	3.6	14
132	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1621-1625	5	14
131	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1297-307	3.5	14
130	Italian Multiple Sclerosis Database Network. <i>Neurological Sciences</i> , <b>2006</b> , 27 Suppl 5, S358-61	3.5	14
129	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 292-301	5	13

128	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 577-587	5	13
127	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 289, 62-7	3.5	13
126	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 46, 102572	4	13
125	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 171, 130-4	3.2	13
124	The CSF p-tau181/A $\beta$ 2 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia. <i>Current Alzheimer Research</i> , <b>2019</b> , 16, 587-595	3	13
123	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , <b>2017</b> , 19, 16-24	2.3	13
122	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , <b>2016</b> , 2016, 2303857	1.1	13
121	Weight gain after subthalamic nucleus deep brain stimulation in Parkinson's disease is influenced by dyskinesias' reduction and electrodes' position. <i>Neurological Sciences</i> , <b>2017</b> , 38, 2123-2129	3.5	12
120	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 342, 167-72	3.2	12
119	Survival prediction models in motor neuron disease. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 1143-11526		11
118	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 535-539	5	11
117	Early treatment. <i>Neurological Sciences</i> , <b>2006</b> , 27 Suppl 1, S8-12	3.5	11
116	Imaging Spinal Cord Damage in Multiple Sclerosis <b>2005</b> , 15, 297-304		11
115	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , <b>2001</b> , 186 Suppl 1, S3-9	3.2	11
114	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e16043	5.5	11
113	Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development. <i>Trends in Pharmacological Sciences</i> , <b>2016</b> , 37, 808-810	13.2	11
112	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 801-810	5	11
111	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	11

110	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 862-70	5	9
109	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , <b>2017</b> , 89, 1265-1273	6.5	9
108	A fatal case of Churg-Strauss syndrome presenting with acute polyneuropathy mimicking Guillain-Barré syndrome. <i>Neurological Sciences</i> , <b>2011</b> , 32, 937-40	3.5	9
107	Neurophysiological imaging techniques in dementia. <i>Neurological Sciences</i> , <b>1999</b> , 20, S265-9	3.5	9
106	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 445-453	6	9
105	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 233-244	5	9
104	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211019574	6.6	9
103	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 33, 75-77	4	8
102	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 968-979	5	8
101	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1918-1928	5	7
100	Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1582-91	12.7	7
99	Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , <b>2019</b> , 124, 109761	4.1	7
98	Evidence for use of glatiramer acetate in multiple sclerosis. <i>Lancet Neurology</i> , <b>2005</b> , 4, 75-6; discussion 76-7	24.1	7
97	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , <b>1999</b> , 17, 985-8	3.3	7
96	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , <b>1999</b> , 246, 97-106	5.5	7
95	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , <b>2020</b> , 43, 635-643	5.1	7
94	Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 401-405	4.3	7
93	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. <i>Neurological Sciences</i> , <b>2018</b> , 39, 373-376	3.5	7



92	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e591	9.1	6
91	Action observation training modifies brain gray matter structure in healthy adult individuals. <i>Brain Imaging and Behavior</i> , <b>2017</b> , 11, 1343-1352	4.1	6
90	Position and practical use of fingolimod in Europe. <i>Clinical and Experimental Neuroimmunology</i> , <b>2014</b> , 5, 19-33	0.4	6
89	Prognosis-modifying therapy in multiple sclerosis. <i>Neurological Sciences</i> , <b>2000</b> , 21, S893-9	3.5	6
88	Visual evoked potentials in diabetic teen-agers: influence of metabolic control and relationship with peripheral neuropathy. <i>Metabolic, Pediatric, and Systemic Ophthalmology</i> , <b>1986</b> , 9, 85-7		6
87	Apparatus design and behavioural testing protocol for the evaluation of spatial working memory in mice through the spontaneous alternation T-maze. <i>Scientific Reports</i> , <b>2021</b> , 11, 21177	4.9	6
86	Oral corticosteroids for multiple sclerosis relapse. <i>Lancet, The</i> , <b>2015</b> , 386, 937-9	4.0	5
85	Digital epidemiology confirms a latitude gradient of MS in France. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 20, 129-131	4	5
84	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , <b>2017</b> , 38, 361-364	3.5	5
83	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective. <i>Multiple Sclerosis International</i> , <b>2015</b> , 2015, 353828	1.1	5
82	Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. <i>Multiple Sclerosis Journal</i> , <b>1997</b> , 3, 93-7	5	5
81	Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data research. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 47, 102634	4	5
80	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2466-71	5.5	4
79	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 443-457	4.6	4
78	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2843-2851	3.5	4
77	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. <i>Neurological Sciences</i> , <b>2012</b> , 33, 949-50	3.5	4
76	Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. <i>Neurological Sciences</i> , <b>2013</b> , 34, 209-15	3.5	4
75	Understanding fatigue in multiple sclerosis: new insights in causes and assessment. <i>Neurological Sciences</i> , <b>2006</b> , 27, s304-s306	3.5	4

74	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	4
73	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (Preprint)		4
72	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , <b>2021</b> ,	6.5	4
71	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1455-1468,	4.8	4
70	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2021</b> , 78, 726-735	17.2	4
69	Added value of multimodal MRI to the clinical diagnosis of primary progressive aphasia variants. <i>Cortex</i> , <b>2019</b> , 113, 58-66	3.8	4
68	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 565-573	5	4
67	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 21-34	4.3	4
66	'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1649-1655	5	3
65	Bi-hemispheric repetitive transcranial magnetic stimulation for upper limb motor recovery in chronic stroke: A feasibility study. <i>Brain Stimulation</i> , <b>2018</b> , 11, 932-934	5.1	3
64	Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 902-907	5	3
63	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 73-76	4	3
62	Neuromyotonia, systemic lupus erythematosus and acetylcholine-receptor antibodies. <i>Journal of Neurology</i> , <b>1998</b> , 245, 182-5	5.5	3
61	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	3
60	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 51, 102844	4	3
59	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 48, 102673	4	3
58	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211032803	5	3
57	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1558-1561	5	2

56	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1005-1007	5.9	2
55	Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". <i>Annals of Neurology</i> , <b>2019</b> , 86, 324	9.4	2
54	Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 41, 102061	4	2
53	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , <b>2018</b> , 138, 447-453	3.8	2
52	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , <b>2017</b> , 11, 1238-1247	4.1	2
51	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , <b>1998</b> , 19, S413-S417		2
50	Electrophysiological correlates of dementia. <i>Supplements To Clinical Neurophysiology</i> , <b>2000</b> , 53, 331-6		2
49	Brain MRI follow-up of patients with persistent isolated optic neuritis. <i>European Journal of Neurology</i> , <b>1996</b> , 3, 36-39	6	2
48	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , <b>2022</b> ,	9.4	2
47	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , <b>2022</b> , 123, 108403	7.7	2
46	Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling for Improving Lower Limb Motor Function After Stroke: An Exploratory Study. <i>Neuromodulation</i> , <b>2021</b> , 24, 916-922	3.1	2
45	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 361, 184-6	3.2	2
44	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 90, 253-265	9.4	2
43	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 3722-3730	6	2
42	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , <b>2021</b> , 38, 4975-4985	4.1	2
41	Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. <i>Electroencephalography and Clinical Neurophysiology Supplement</i> , <b>1996</b> , 46, 85-93		2
40	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , <b>2019</b> , 266, 3098-3107	5.5	1
39	Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2019</b> , 20, 449-452	3.6	1

38	Multiple sclerosis progression is not associated with birth timing in Italy. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 346, 194-6	3.2	1
37	Natalizumab: state of the art and open questions. <i>Neurological Sciences</i> , <b>2011</b> , 31 Suppl 3, 313-5	3.5	1
36	Treatment of chronic inflammatory demyelinating polyneuropathy. <i>Italian Journal of Neurological Sciences</i> , <b>1998</b> , 19, 261-9		1
35	Definition of responder: introduction. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S209-10	3.5	1
34	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	1
33	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study (Preprint)		1
32	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 384, 58-60	3.2	1
31	Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 408, 116573	3.2	1
30	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon $\beta$ 1a. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 39, 101891	4	1
29	A new electrophysiological non-invasive method to assess retinocortical conduction time in the Dark Agouti rat through the simultaneous recording of electroretinogram and visual evoked potential. <i>Documenta Ophthalmologica</i> , <b>2020</b> , 140, 245-255	2.2	1
28	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , <b>2020</b> , 20, 364	3.1	1
27	Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation. <i>Molecules</i> , <b>2020</b> , 25,	4.8	1
26	Functional evolution of visual involvement in experimental autoimmune encephalomyelitis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320963474	2	1
25	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , <b>2016</b> , 23, e39-40	6	1
24	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 57-59	4	1
23	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 430-438	5	1
22	Letter to the Editor Regarding: A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2018</b> , 7, 385-390	4.6	1
21	039 Rates of lymphopenia in years 1-4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A16.2-A16	5.5	1

20	The 4-Hole-Board Test for Assessment of Long-Term Spatial Memory in Mice. <i>Current Protocols</i> , <b>2021</b> , 1, e228		1
19	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 2055217321990852	2	1
18	The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Italian Diabetic Neuropathy Committee. <i>Electroencephalography and Clinical Neurophysiology Supplement</i> , <b>1999</b> , 50, 546-52		1
17	Optic neuritis in multiple sclerosis: Looking from a patient's eyes. <i>Neurology</i> , <b>2016</b> , 87, 338-9	6.5	0
16	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 417, 117064	3.2	0
15	Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1222-1229	5	0
14	DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S088-S089	1.5	0
13	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 61, 103757	4	0
12	Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes.. <i>Frontiers in Neuroscience</i> , <b>2022</b> , 16, 820155	5.1	0
11	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , <b>2022</b> , 98, e1626-e1636	6.5	0
10	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 103909	4	0
9	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. <i>Journal of Pediatric Neurology</i> , <b>2015</b> , 09, 497-500	0.2	
8	Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging <b>2016</b> , 163-187		
7	Introduction. <i>Neurological Sciences</i> , <b>1999</b> , 20, S227-8	3.5	
6	Interferon beta treatment in multiple sclerosis: the European clinical trials. <i>Multiple Sclerosis Journal</i> , <b>1996</b> , 1, 317-20	5	
5	Neurophysiology <b>2002</b> , 25-33		
4	Teaching NeuroImages: Osteolytic intraosseous meningioma causing transcalvarial herniation. <i>Neurology</i> , <b>2020</b> , 95, e1110-e1111	6.5	
3	040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A17.1-A17	5.5	

- 2 067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, A27.2-A28 5.5
- 1 Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173221099181 2